Decreased Expression of Dual-specificity Phosphatase 9 is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2011 Sep 28

PMID 21943117

Citations 17

Authors

Song Wu

Yong Wang

Liang Sun

Zhiling Zhang

Zhimao Jiang

Zike Qin

Hui Han

Zhuowei Liu

Xianxin Li

Aifa Tang

Yaoting Gui

Zhiming Cai

Fangjian Zhou

Affiliations

Soon will be listed here.

Abstract

Background: The molecular mechanisms involved in the development and progression of clear cell renal cell carcinomas (ccRCCs) are poorly understood. The objective of this study was to analyze the expression of dual-specificity phosphatase 9 (DUSP-9) and determine its clinical significance in human ccRCCs.

Methods: The expression of DUSP-9 mRNA was determined in 46 paired samples of ccRCCs and adjacent normal tissues by using real-time qPCR. The expression of the DUSP-9 was determined in 211 samples of ccRCCs and 107 paired samples of adjacent normal tissues by immunohistochemical analysis. Statistical analysis was performed to define the relationship between the expression of DUSP-9 and the clinical features of ccRCC.

Results: The mRNA level of DUSP-9, which was determined by real-time RT-PCR, was found to be significantly lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). An immunohistochemical analysis of 107 paired tissue specimens showed that the DUSP-9 expression was lower in tumorous tissues than in the adjacent non-tumorous tissues (p < 0.001). Moreover, there was a significant correlation between the DUSP-9 expression in ccRCCs and gender (p = 0.031), tumor size (p = 0.001), pathologic stage (p = 0.001), Fuhrman grade (p = 0.002), T stage (p = 0.001), N classification (p = 0.012), metastasis (p = 0.005), and recurrence (p < 0.001). Patients with lower DUSP-9 expression had shorter overall survival time than those with higher DUSP-9 expression (p < 0.001). Multivariate analysis indicated that low expression of the DUSP-9 was an independent predictor for poor survival of ccRCC patients.

Conclusion: To our knowledge, this is the first study that determines the relationship between DUSP-9 expression and prognosis in ccRCC. We found that decreased expression of DUSP-9 is associated with poor prognosis in ccRCC. DUSP-9 may represent a novel and useful prognostic marker for ccRCC.

Citing Articles

Dual-Specificity Phosphatases in Regulation of Tumor-Associated Macrophage Activity.

Patysheva M, Prostakishina E, Budnitskaya A, Bragina O, Kzhyshkowska J Int J Mol Sci. 2023; 24(24).

PMID: 38139370 PMC: 10743672. DOI: 10.3390/ijms242417542.

DUSP9, a Dual-Specificity Phosphatase with a Key Role in Cell Biology and Human Diseases.

Khoubai F, Grosset C Int J Mol Sci. 2021; 22(21).

PMID: 34768967 PMC: 8583968. DOI: 10.3390/ijms222111538.

Dual-Specificity Phosphatase 9 Regulates Cellular Proliferation and Predicts Recurrence After Surgery in Hepatocellular Carcinoma.

Chen K, Gorgen A, Ding A, Du L, Jiang K, Ding Y Hepatol Commun. 2021; 5(7):1310-1328.

PMID: 34278178 PMC: 8279460. DOI: 10.1002/hep4.1701.

DUSP9-mediated reduction of pERK1/2 supports cancer stem cell-like traits and promotes triple negative breast cancer.

Jimenez T, Barrios A, Tucker A, Collazo J, Arias N, Fazel S Am J Cancer Res. 2020; 10(10):3487-3506.

PMID: 33163285 PMC: 7642669.

Downregulation of DUSP9 Promotes Tumor Progression and Contributes to Poor Prognosis in Human Colorectal Cancer.

Qiu Z, Liang N, Huang Q, Sun T, Xue H, Xie T Front Oncol. 2020; 10:547011.

PMID: 33072575 PMC: 7538709. DOI: 10.3389/fonc.2020.547011.

References

McLaughlin J, Lipworth L, Tarone R . Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 2006; 33(5):527-33. DOI: 10.1053/j.seminoncol.2006.06.010. View

Janzen N, Kim H, Figlin R, Belldegrun A . Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003; 30(4):843-52. DOI: 10.1016/s0094-0143(03)00056-9. View

Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View

Christie G, Williams D, Macisaac F, Dickinson R, Rosewell I, Keyse S . The dual-specificity protein phosphatase DUSP9/MKP-4 is essential for placental function but is not required for normal embryonic development. Mol Cell Biol. 2005; 25(18):8323-33. PMC: 1234323. DOI: 10.1128/MCB.25.18.8323-8333.2005. View

Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P . The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008; 101(8):949-58. DOI: 10.1111/j.1464-410X.2008.07451.x. View

Ljungberg B, Cowan N, Hanbury D, Hora M, Kuczyk M, Merseburger A . EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010; 58(3):398-406. DOI: 10.1016/j.eururo.2010.06.032. View

Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View

Keyse S . Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol. 2000; 12(2):186-92. DOI: 10.1016/s0955-0674(99)00075-7. View

McCredie M . Bladder and kidney cancers. Cancer Surv. 1994; 19-20:343-68. View

10.

Zhang Z, Li J, Zheng H, Yu C, Chen J, Liu Z . Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18(10):2685-93. DOI: 10.1158/1055-9965.EPI-09-0097. View

11.

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

12.

Sun H, Tonks N, Bar-Sagi D . Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science. 1994; 266(5183):285-8. DOI: 10.1126/science.7939666. View

13.

Saussez S, Cucu D, Decaestecker C, Chevalier D, Kaltner H, Andre S . Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol. 2006; 13(7):999-1009. DOI: 10.1245/ASO.2006.08.033. View

14.

Brondello J, Brunet A, Pouyssegur J, McKenzie F . The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J Biol Chem. 1997; 272(2):1368-76. DOI: 10.1074/jbc.272.2.1368. View

15.

Sabatino M, Kim-Schulze S, Panelli M, Stroncek D, Wang E, Taback B . Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009; 27(16):2645-52. PMC: 2689845. DOI: 10.1200/JCO.2008.19.1106. View

16.

Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler M, Korc M . Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology. 2003; 124(7):1830-45. DOI: 10.1016/s0016-5085(03)00398-6. View

17.

Lewis T, Shapiro P, Ahn N . Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998; 74:49-139. DOI: 10.1016/s0065-230x(08)60765-4. View

18.

Banks R, Craven R, Harnden P, Madaan S, Joyce A, Selby P . Key clinical issues in renal cancer: a challenge for proteomics. World J Urol. 2007; 25(6):537-56. DOI: 10.1007/s00345-007-0199-y. View

19.

Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M . Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell. 2004; 5(4):329-39. DOI: 10.1016/s1535-6108(04)00081-9. View

20.

Buchner A, Castro M, Hennig A, Popp T, Assmann G, Stief C . Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis. Urology. 2010; 76(2):507.e6-11. DOI: 10.1016/j.urology.2010.03.042. View